These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms.
    Author: Mizunuma H.
    Journal: Climacteric; 2011 Oct; 14(5):581-9. PubMed ID: 21848497.
    Abstract:
    OBJECTIVES: To determine the efficacy and safety of low-dose maintenance therapy with transdermal estradiol (E2) gel in Japanese women with climacteric disorder and estrogen deficiency symptoms. METHODS: Women (n = 209) aged 37-59 years who had climacteric disorder or estrogen deficiency symptoms received a standard dose of transdermal E2 gel (1.8 g/day, containing E2 1.08 mg/day) for 8 weeks as induction treatment. A total of 177 women in whom the number of daily hot flushes had decreased to less than one-third of the baseline value (marked improvement) at week 8 were double-blindly randomized to receive low-dose E2 (n = 88, 0.9 g/day, containing E2 0.54 mg/day) or E2-free placebo (n = 89) for 16 weeks. RESULTS: Improvement rates in the number of daily hot flushes at the final evaluation (primary endpoint) in the low-dose E2 group (marked 90.8%, moderate 6.9%, mild 1.1%, no change 1.1%, worsening 0%) were significantly greater than in the placebo group (marked 77.0%, moderate 10.3%, mild 4.6%, no change 2.3%, worsening 5.7%) (p = 0.0097), showing an inhibitive effect on the flare-up of climacteric symptoms. The incidence of treatment-related adverse events in the low-dose group (21.6%) was similar to that in the placebo (22.5%) but was lower than that in the standard-dose treatment (32.5%). CONCLUSIONS: Low-dose maintenance therapy that was half the standard dose of transdermal E2 gel (0.9 g/day) applied to women who had achieved marked improvement in the number of hot flushes at the standard dose (1.8 g/day) was demonstrated to be effective (inhibition of recurrence) and safe for the treatment of climacteric disorder and estrogen deficiency symptoms.
    [Abstract] [Full Text] [Related] [New Search]